PURPOSE: To investigate combined MRI and 18F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathological response and recurrence-free survival (RFS) in women treated for breast cancer. METHODS: Patients undergoing neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer were imaged at three timepoints (pre, mid, and post-NAC), prior to surgery. Imaging included diffusion-weighted and dynamic contrast-enhanced (DCE-) MRI and quantitative 18F-FDG PET. Tumor imaging measures included apparent diffusion coefficient, peak percent enhancement (PE), peak signal enhancement ratio (SER), functional tumor volume, and washout volume on MRI and standardized uptake value (SUVmax), glucose delivery (K1) and FDG metabolic rate (MRFDG) on PET, with percentage changes from baseline calculated at mid- and post-NAC. Associations of imaging measures with pathological response (residual cancer burden [RCB] 0/I vs. II/III) and RFS were evaluated. RESULTS: Thirty-five patients with stage II/III invasive breast cancer were enrolled in the prospective study (median age: 43, range: 31-66 years, RCB 0/I: N = 11/35, 31%). Baseline imaging metrics were not significantly associated with pathologic response or RFS (p > 0.05). Greater mid-treatment decreases in peak PE, along with greater post-treatment decreases in several DCE-MRI and 18F-FDG PET measures were associated with RCB 0/I after NAC (p < 0.05). Additionally, greater mid- and post-treatment decreases in DCE-MRI (peak SER, washout volume) and 18F-FDG PET (K1) were predictive of prolonged RFS. Mid-treatment decreases in metabolism/perfusion ratios (MRFDG/peak PE, MRFDG/peak SER) were associated with improved RFS. CONCLUSION: Mid-treatment changes in both PET and MRI measures were predictive of RCB status and RFS following NAC. Specifically, our results indicate a complementary relationship between DCE-MRI and 18F-FDG PET metrics and potential value of metabolism/perfusion mismatch as a marker of patient outcome.

American Society of Clinical Oncology Alexandria VA USA

Charles University and Thomayer University Hospital Prague Czech Republic

Department of Radiology University of Pennsylvania Philadelphia PA USA

Department of Radiology University of Washington Fred Hutchinson Cancer Center Seattle WA USA

Division of Hematology and Oncology University of Washington Fred Hutchinson Cancer Center 1144 Eastlake Seattle WA 98109 1023 USA

Fred Hutchinson Cancer Consortium Seattle WA USA

Zobrazit více v PubMed

Tong CWS, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. Front Oncol. 2018 doi: 10.3389/fonc.2018.00227. PubMed DOI PMC

I-SPY2 Trial Consortium. Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020;6(9):1355. doi: 10.1001/jamaoncol.2020.2535. PubMed DOI PMC

Yankeelov TE, Abramson RG, Quarles CC. Quantitative multimodality imaging in cancer research and therapy. Nat Rev Clin Oncol. 2014;11(11):670–680. doi: 10.1038/nrclinonc.2014.134. PubMed DOI PMC

Sorace AG, Harvey S, Syed A, Yankeelov TE. Imaging considerations and interprofessional opportunities in the care of breast cancer patients in the neoadjuvant setting. Semin Oncol Nurs. 2017;33(4):425–439. doi: 10.1016/j.soncn.2017.08.008. PubMed DOI PMC

Tseng J, Dunnwald LK, Schubert EK, Link JM, Minoshima S, Muzi M, et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med. 2004;45(11):1829–1837. PubMed

Partridge SC, Nissan N, Rahbar H, Kitsch AE, Sigmund EE. Diffusion-weighted breast MRI: clinical applications and emerging techniques. J Magn Reson Imaging. 2017;45(2):337–355. doi: 10.1002/jmri.25479. PubMed DOI PMC

Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, et al. Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival—results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2015;279(1):44–55. doi: 10.1148/radiol.2015150013. PubMed DOI PMC

Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]Fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24(34):5366–5372. doi: 10.1200/JCO.2006.05.7406. PubMed DOI

Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, et al. Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial. Radiology. 2018;289(3):618–627. doi: 10.1148/radiol.2018180273. PubMed DOI PMC

Partridge SC, Vanantwerp RK, Doot RK, Chai X, Kurland BF, Eby PR, et al. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging. 2010;32(5):1124–1131. doi: 10.1002/jmri.22362. PubMed DOI PMC

Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, et al. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and 15O-water positron emission tomography blood flow in breast cancer. Acad Radiol. 2008;15(10):1246–1254. doi: 10.1016/j.acra.2008.03.019. PubMed DOI PMC

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43(4):500–509. PubMed

Mankoff DA, Dunnwald LK, Partridge SC, Specht JM. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res. 2009;15(17):5294–5296. doi: 10.1158/1078-0432.CCR-09-1448. PubMed DOI PMC

Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res. 2010;16(10):2803–2810. doi: 10.1158/1078-0432.CCR-10-0026. PubMed DOI PMC

Semple S. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol. 2006;17(9):1393–1398. doi: 10.1093/annonc/mdl136. PubMed DOI

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(9):2206–2223. doi: 10.1093/annonc/mdt303. PubMed DOI PMC

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44(11):1806–1814. PubMed

Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, et al. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology. 2008;248(1):79–87. doi: 10.1148/radiol.2481070846. PubMed DOI PMC

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–4422. doi: 10.1200/JCO.2007.10.6823. PubMed DOI

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JAW, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127–2132. doi: 10.1200/JCO.2006.10.3523. PubMed DOI

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026. PubMed DOI

Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012;263(3):663–672. doi: 10.1148/radiol.12110748. PubMed DOI PMC

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26(27):4449–4457. doi: 10.1200/JCO.2007.15.4385. PubMed DOI PMC

Jordan BF, Sonveaux P. Targeting tumor perfusion and oxygenation modulates hypoxia and cancer sensitivity to radiotherapy and systemic therapies. In: Gali-Muhtasib H (ed) Advances in cancer therapy [Internet]. InTech; 2011 [cited 2021 Sep 10]. http://www.intechopen.com/books/advances-in-cancer-therapy/targeting-tumor-perfusion-and-oxygenation-modulates-hypoxia-and-cancer-sensitivity-to-radiotherapy-a.

Karan B, Pourbagher A, Torun N. Diffusion-weighted imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors. J Magn Reson Imaging. 2016;43(6):1434–1444. doi: 10.1002/jmri.25112. PubMed DOI

Baba S, Isoda T, Maruoka Y, Kitamura Y, Sasaki M, Yoshida T, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med. 2014;55(5):736–742. doi: 10.2967/jnumed.113.129395. PubMed DOI

Syed AK, Woodall R, Whisenant JG, Yankeelov TE, Sorace AG. Characterizing trastuzumab-induced alterations in intratumoral heterogeneity with quantitative imaging and immunohistochemistry in HER2+ breast cancer. Neoplasia. 2019;21(1):17–29. doi: 10.1016/j.neo.2018.10.008. PubMed DOI PMC

Granzier RWY, van Nijnatten TJA, Woodruff HC, Smidt ML, Lobbes MBI. Exploring breast cancer response prediction to neoadjuvant systemic therapy using MRI-based radiomics: a systematic review. Eur J Radiol. 2019;121:108736. doi: 10.1016/j.ejrad.2019.108736. PubMed DOI

Cortazar P, Geyer CE. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441–1446. doi: 10.1245/s10434-015-4404-8. PubMed DOI

Pujara AC, Kim E, Axelrod D, Melsaether AN. PET/MRI in breast cancer. J Magn Reson Imaging. 2019;49(2):328–342. doi: 10.1002/jmri.26298. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01931709